A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs HDM 201 (Primary) ; Ribociclib (Primary)
- Indications Liposarcoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 29 Sep 2017 Planned number of patients changed from 107 to 108.
- 01 Mar 2017 Planned number of patients changed from 84 to 107.
- 01 Mar 2017 Planned End Date changed from 1 Mar 2018 to 29 Dec 2018.